Myriad Awaits BRACAnalysis CDx Approval as it Works to Move Hereditary Cancer Testing to MyRisk | GenomeWeb

NEW YORK (GenomeWeb) — Fiscal year 2015 will see a significant shift for Myriad Genetics in hereditary cancer testing, as it aims to move all of its comprehensive BRACAnanlysis customers to its newer sequencing-based myRisk Hereditary Cancer panel by mid-2015.

Meanwhile, the company is hoping the US Food and Drug Administration will soon approve the companion diagnostic version of BRACAnalysis alongside AstraZeneca's olaparib

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.